Abstract
Introduction: Treatment complexity can impact treatment adherence, which may affect clinical outcomes in people with T2D. This analysis assessed PROs in the SoliMix trial.Methods: SoliMix, an open-label, multicenter study, randomized adults with T2D and HbA1c ≥7.5-≤10 % on BI + OADs to once-daily iGlarLixi or twice-daily premix insulin analog (BiAsp 70/30). Between-treatment differences from baseline to Week 26 (W26) in Treatment-Related Impact Measure for Diabetes (TRIM-D) scores are shown overall and by domain. Global Treatment Effectiveness Evaluation (GTEE) endpoints were analyzed descriptively at W26.Results: As well as providing better glycemic control, iGlarLixi demonstrated greater improvement in each TRIM-D domain vs. BiAsp 70/30 from baseline to W26 (Figure), with the greatest differences seen in diabetes management and treatment burden scores. GTEE scores also showed a greater proportion of participants and physicians who rated complete or marked improvement of diabetes control with iGlarLixi (81% and 83%) vs. BiAsp 70/30 (63% and 65%) at W26.Conclusions: Advancing BI with iGlarLixi resulted in a greater positive impact than with premix 70/30 for people with T2D uncontrolled on BI + OADs, suggesting a potentially lower treatment burden with iGlarLixi.View largeDownload slideView largeDownload slide DisclosureW. H. Polonsky: Advisory Panel; Self; Intarcia Therapeutics, Inc., Consultant; Self; Abbott Diabetes, ADOCIA, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Insulet Corporation, Lilly Diabetes, Novo Nordisk, Onduo LLC., Sanofi US. J. Rosenstock: Board Member; Self; Applied Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Inc., Novo Nordisk, Oramed Pharmaceuticals, Inc., Sanofi, Consultant; Self; Applied Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Inc., Novo Nordisk, Oramed Pharmaceuticals, Inc., Sanofi, Research Support; Self; Applied Therapeutics, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Genentech, Inc., Intarcia Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Oramed Pharmaceuticals, Inc., Pfizer Inc., REMD Biotherapeutics, Sanofi. R. J. Mccrimmon: Advisory Panel; Self; Novo Nordisk Inc., Sanofi-Aventis, Board Member; Self; Novo Nordisk Foundation, Research Support; Self; AstraZeneca. K. H. Whitmire: None. F. Giorgino: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk, Roche Diabetes Care, Sanofi, Research Support; Self; Lilly Diabetes, Roche Diabetes Care. J. Chen: None. C. Nicholls: Employee; Self; Sanofi. E. Lew: Employee; Self; Sanofi. A. Alvarez: Employee; Self; Sanofi. M. Coudert: Employee; Self; Sanofi.FundingSanofi (EudraCT 2017-003370-13)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call